Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Durect Corp. (DRRX)
NASDAQ:DRRX
Holding DRRX?
Track your performance easily
DRRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.47 - $3.14
Previous Close$1.35
Volume89.04K
Average Volume (3M)78.94K
Market Cap
$41.90M
Enterprise Value$42.32M
Total Cash (Recent Filing)$15.65M
Total Debt (Recent Filing)$16.06M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Nov 04, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding31,039,381
10 Day Avg. Volume73,100
30 Day Avg. Volume78,944
Standard Deviation0.29
R-Squared0.04
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)8.56
Price to Sales (P/S)4.98
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.41
Enterprise Value/Gross Profit6.20
Enterprise Value/Ebitda-1.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Durect News
PremiumCompany Announcements
Durect Grants CFO Tim Papp Incentive Stock Package
Bulls Say, Bears Say
Bulls Say
Clinical StudiesThe FDA has agreed to a single pivotal study, which is to enroll patients only from U.S. sites.
Drug DevelopmentThe FDA's BTD provides multiple advantages to speed up larsucosterol's development timeline.
FDA ApprovalThe recent Breakthrough Therapy designation (BTD) is viewed as strong validation of the drug's value in AH.
Bears Say
Capital ManagementWith a current cash runway of about 4½ months, DURECT says 'everything is on the table' in terms of alternatives to raise capital.
Clinical TrialsLarsucosterol did not reach statistical significance for either dose in both the primary and key secondary endpoints in the total study population.
Market UncertaintyThere remains significant uncertainty regarding larsucosterol's time to market in AH to provide a reasonable basis for valuing the shares.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DRRX FAQ
What was Durect Corp.’s price range in the past 12 months?
Durect Corp. lowest stock price was $0.47 and its highest was $3.14 in the past 12 months.
What is Durect Corp.’s market cap?
Currently, no data Available
When is Durect Corp.’s upcoming earnings report date?
Durect Corp.’s upcoming earnings report date is Nov 04, 2024 which is in 45 days.
How were Durect Corp.’s earnings last quarter?
Durect Corp. released its earnings results on Aug 13, 2024. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.163 by $0.043.
Is Durect Corp. overvalued?
According to Wall Street analysts Durect Corp.’s price is currently Overvalued.
Does Durect Corp. pay dividends?
Durect Corp. does not currently pay dividends.
What is Durect Corp.’s EPS estimate?
Durect Corp.’s EPS estimate is -$0.2.
How many shares outstanding does Durect Corp. have?
Durect Corp. has 31,039,381 shares outstanding.
What happened to Durect Corp.’s price movement after its last earnings report?
Durect Corp. reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.163. Following the earnings report the stock price went down -5.674%.
Which hedge fund is a major shareholder of Durect Corp.?
Among the largest hedge funds holding Durect Corp.’s share is Moore Capital Management LP. It holds Durect Corp.’s shares valued at N/A.
---
Durect Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
DRRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 75.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.90%
12-Months-Change
Fundamentals
Return on Equity
-299.88%
Trailing 12-Months
Asset Growth
-38.64%
Trailing 12-Months
Company Description
Durect Corp.
DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
---
DRRX Earnings Call
Q2 2024
0:00 / 0:00
---
DRRX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering DRRX
1 Year
1 Year Success Rate
2/16 ratings generated profit
1 Year Average Return
-39.44%
reiterated a buy rating 4 months ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -39.44% per trade.
---